Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sabakem pty ltd - ametryn - unknown - ametryn triazine active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zhejiang zhongshan chemical industry group co.,ltd - ametryn - unknown - ametryn triazine active 0.0 - active constituent

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - american house dust mite extract, quantity: 5 ir/ml; european house dust mite extract, quantity: 5 ir/ml - injection, suspension - excipient ingredients: sodium chloride; phenol; water for injections; aluminium hydroxide hydrate; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Ireland - English - HPRA (Health Products Regulatory Authority)

bioforce (uk) ltd - tincture from fresh echinacea purpurea (l.) moench herb (1:12). extraction solvent: ethanol 65% v/v, tincture from fresh echinacea purpurea (l.) moench root (1:11). extraction solvent: 65 %v/v - concentrate for oral solution - 5 millilitre

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; citric acid - breast cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease adjuvant treatment of breast cancer docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2 docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of = 1 cm and < 7 cm. non small cell lung cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum-based chemotherapy. ovarian cancer docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. head and neck cancer docetaxel in combination with cisplatin and fluorouracil, is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - docetaxel, quantity: 160 mg - injection, concentrated - excipient ingredients: citric acid; ethanol absolute; polysorbate 80 - breast cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease adjuvant treatment of breast cancer docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2 docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of = 1 cm and < 7 cm. non small cell lung cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum-based chemotherapy. ovarian cancer docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. head and neck cancer docetaxel in combination with cisplatin and fluorouracil, is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - cypermethrin; hydrocarbon solvent - emulsifiable concentrate - cypermethrin pyrethroid active 250.0 g/l; hydrocarbon solvent solvent other 624.0 g/l - insecticide - barley | bush tomato | cereals | cotton | faba bean | field pea | lupin | maize | mung bean | navy bean | sorghum | soybean | su - cluster caterpillar | common armyworm | corn earworm | cotton budworm or bollworm | cotton looper | cutworm | grey cluster bug | lesser armyworm | native budworm or bollworm | pea weevil | plague thrips | rough bollworm | rutherglen bug | sorghum midge | southern or barley armyworm | soybean looper | tobacco budworm | tomato grub | webworm | barley armyworm | barley grub | corn earworm | cotton bollworm | diachrysia orichalceaa | heliothis | native bollworm | southern armyworm | tobacco budworm | tomato grub

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

4 farmers australia pty ltd - fluazifop-p present as the butyl ester; hydrocarbon solvent - emulsifiable concentrate - fluazifop-p present as the butyl ester phenoxy acids-propionics active 212.0 g/l; hydrocarbon solvent solvent other 703.0 g/l - herbicide - akee | apple | avocado | axillaris forage crop | axillaris seed crop | banana | bargoo jointvetch forage crop | bargoo jointvetc - annual grass weed | annual or wimmera ryegrass | annual phalaris | annual ryegrass | barley grass | barnyard grass or water grass | barnyard or water grass | bent grass - agrostis spp. | brome grass | carpet grass | couch - seedling | couch grass | crowsfoot grass | english couch - seedling | english couch or rope twitch | foxtail - seedling | green panic - seedling | green summer grass | guinea grass | innocent weed or grass | johnson grass | johnson grass - seedling | kentucky bluegrass | kikuyu grass | liverseed or urochloa grass | para grass | paspalum | paspalum - seedling | pasture | perennial grass weed - seedling | pigeon grass | pigeon grass - seedling | prairie grass | rhodes grass | stink grass | summer or crab grass | vasey grass | vasey grass - seedling | veldtgrass | volunteer cereal | water couch | water couch - seedling | wild oat | abyssinian rhodes grass | agropyron repens | agrostis capillaris | annual grasses | annual summer grass | barnyard grass | bromus diandrus | bromus rigidus | canar

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - golimumab, quantity: 50 mg - solution - excipient ingredients: water for injections; histidine; histidine hydrochloride monohydrate; sorbitol; polysorbate 80 - simponi iv,rheumatoid arthritis (ra),simponi iv, in combination with methotrexate, is indicated for:,the treatment of moderate to severely active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drug therapy, including methotrexate, has been inadequate. simponi iv has also been shown to inhibit the progression of joint damage as measured by x-ray.,psoriatic arthritis (psa),simponi iv, alone or in combination with methotrexate, is indicated for:,the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.,ankylosing spondylitis (as),simponi iv is indicated for:,the treatment of active ankylosing spondylitis in adult patients

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: acesulfame potassium; purified water; maltitol solution; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; propyl hydroxybenzoate; sodium citrate dihydrate; glycerol; flavour - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.